ArticleInfection and drug resistance2026
Daptomycin Dosing Based on Adjusted Body Weight in Obese Patients versus Actual Body Weight: A Multicentre Cohort Study.
Article in Infection and drug resistance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Daptomycin-approved dosing is based on actual body weight (ABW). However, the pharmacokinetics and pharmacodynamics of daptomycin are altered in obese patients, leading to increased daptomycin exposure owing to incomplete distribution into excess body tissues. Data regarding the use of alternative weight descriptors for daptomycin dosing are limited. This study aimed to investigate the effectiveness and safety of daptomycin in obese patients by using adjusted body weight (AdjBW). Methods: This retrospective multicenter cohort study in Saudi Arabia compared the outcomes of obese patients who received daptomycin based on AdjBW with those of obese and non-obese patients who received daptomycin based on ABW. The main outcomes included clinical cure, overall in-hospital mortality, and 30-day mortality. The safety outcomes were evaluated. Multivariate logistic regression was used to control for confounding variables. Results: A total of 293 patients met the inclusion: 43 patients in AdjBW group, 54 in the ABW group, and 196 in the non-obese group. When comparing the AdjBW and ABW obese groups, no statistically significant difference was observed in clinical cure (83.7% vs 77.8%; p = 0.461; OR, 0.1.47; 95% CI, 0.52-4.12), overall in-hospital mortality (23.3% vs 35.2%; p = 0.200; OR, 0.56; 95% CI, 0.23-1.37), or 30-day mortality (16.3% vs 27.8%; p = 0.174; OR, 0.51; 95% CI, 0.19-1.38). Creatine phosphokinase elevation (8.6% vs 6%; p = 0.651) was similar between the two groups. Similar outcomes were observed when comparing the AdjBW and non-obese groups. Conclusion: Treatment with daptomycin based on AdjBW in obese patients had similar effectiveness and safety outcomes as treatment with daptomycin based on ABW in obese and non-obese patients. Therefore, future prospective studies are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.